WallStreetZenWallStreetZen

NASDAQ: RVPH
Reviva Pharmaceuticals Holdings Inc Stock

Overview
ForecastEarningsDividendOwnership
$4.01-0.08 (-1.96%)
Updated Dec 8, 2023
RVPH Price
$4.01
Fair Value Price
$4.53
Market Cap
$90.83M
52 Week Low
$3.03
52 Week High
$9.25
P/E
-2.4x
P/B
-10.66x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$37.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.63
Operating Cash Flow
-$24M
Beta
0.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

RVPH Overview

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

Zen Score

–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RVPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RVPH ($4.01) is undervalued by 11.39% relative to our estimate of its Fair Value price of $4.53 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RVPH ($4.01) is not significantly undervalued (11.39%) relative to our estimate of its Fair Value price of $4.53 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RVPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RVPH due diligence checks available for Premium users.

Be the first to know about important RVPH news, forecast changes, insider trades & much more!

RVPH News

Valuation

RVPH fair value

Fair Value of RVPH stock based on Discounted Cash Flow (DCF)
Price
$4.01
Fair Value
$4.53
Undervalued by
11.39%
RVPH ($4.01) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RVPH ($4.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RVPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RVPH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.4x
Industry
11.7x
Market
31.32x

RVPH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-10.66x
Industry
5.42x

RVPH's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.5M
Profit Margin
0%

Assets to liabilities

Assets
$5.4M
Liabilities
$13.9M
Debt to equity
-1.63
RVPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RVPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.2M
Investing
$0.0
Financing
$0.0

RVPH vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RVPH$90.83M-1.96%-2.40x-10.66x
ADVM$90.92M-10.89%-0.71x0.89x
ORMP$90.36M-0.44%-5.46x0.61x
MDWD$89.98M+5.29%-5.28x2.72x
IKNA$91.69M+8.57%-1.17x0.59x
View Top Biotech Stocks

Reviva Pharmaceuticals Holdings Stock FAQ

What is Reviva Pharmaceuticals Holdings's quote symbol?

(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings trades on the NASDAQ under the ticker symbol RVPH. Reviva Pharmaceuticals Holdings stock quotes can also be displayed as NASDAQ: RVPH.

If you're new to stock investing, here's how to buy Reviva Pharmaceuticals Holdings stock.

What is the 52 week high and low for Reviva Pharmaceuticals Holdings (NASDAQ: RVPH)?

(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's 52-week high was $9.25, and its 52-week low was $3.03. It is currently -56.65% from its 52-week high and 32.34% from its 52-week low.

How much is Reviva Pharmaceuticals Holdings stock worth today?

(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings currently has 22,650,266 outstanding shares. With Reviva Pharmaceuticals Holdings stock trading at $4.01 per share, the total value of Reviva Pharmaceuticals Holdings stock (market capitalization) is $90.83M.

Reviva Pharmaceuticals Holdings stock was originally listed at a price of $10.03 in Aug 21, 2018. If you had invested in Reviva Pharmaceuticals Holdings stock at $10.03, your return over the last 5 years would have been -60.02%, for an annualized return of -16.75% (not including any dividends or dividend reinvestments).

How much is Reviva Pharmaceuticals Holdings's stock price per share?

(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings stock price per share is $4.01 today (as of Dec 8, 2023).

What is Reviva Pharmaceuticals Holdings's Market Cap?

(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's market cap is $90.83M, as of Dec 11, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Reviva Pharmaceuticals Holdings's market cap is calculated by multiplying RVPH's current stock price of $4.01 by RVPH's total outstanding shares of 22,650,266.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.